(62 days)
Not Found
Not Found
No
The description details a chemical assay method for measuring LDL-C, relying on enzymatic reactions and spectrophotometry. There is no mention of AI or ML in the device description, intended use, or performance studies.
No.
This device is for the quantitative determination of LDL-C in human serum or plasma, which is a diagnostic purpose, not a therapeutic one.
Yes
The device is intended for the "direct, quantitative determination of low-density lipoprotein cholesterol (LDL-C) in human serum or plasma," which provides specific biochemical information used to diagnose conditions related to cholesterol levels.
No
The device description clearly states it is a "two-reagent homogeneous method" and describes chemical reactions and components, indicating it is a physical reagent kit, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "For the direct, quantitative determination of low-density lipoprotein cholesterol (LDL-C) in human serum or plasma." This indicates the device is used to test samples taken from the human body (in vitro) to provide diagnostic information (determining LDL-C levels).
- Device Description: The description details a "homogeneous method for the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum and plasma." This further confirms its use in analyzing biological samples.
- Reagents, Calibrator, and Controls: The mention of reagents, a calibrator, and controls are all characteristic components of IVD kits used for performing diagnostic tests on biological samples.
- Clinical Laboratory Setting: The intended user/care setting is a "clinical laboratory setting," which is where IVD tests are typically performed.
The information provided clearly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Reagents: For the direct, quantitative determination of low-density lipoprotein cholesterol (LDL-C) in human serum or plasma.
Calibrator: For the calibration of the N-geneous® LDL-ST Cholesterol assay in serum or plasma.
Controls: To monitor the performance of the Genzyme Direct LDL Cholesterol, N-geneous® LDL Cholesterol and N-geneous® LDL-ST Cholesterol Reagents.
Product codes (comma separated list FDA assigned to the subject device)
MRR, JIS, JJX
Device Description
The Genzyme N-geneous® LDL-ST Cholesterol Reagent is a two-reagent homogeneous method for the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum and plasma. This method is applicable to Olympus two-reagent Chemistry Analyzers and does not require any off-line pretreatment or centrifugation steps.
The principle of the test is based upon a unique detergent which selectively solubilizes only the non-LDL lipoproteins, allowing them to be removed by cholesterol enzymes prior to the LDL cholesterol reaction. The LDL particles remain intact. The hydrogen peroxide produced by the reaction of the enzymes with the released cholesterol is consumed by a peroxidase reaction with 4-aminoantipyrine, yielding a colorless product. A second detergent, capable of releasing LDL cholesterol molecules, is added. The enzyme reaction with LDL cholesterol in the presence of the coupler produces color which is proportional to the amount of LDL cholesterol in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratory setting
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Comparative performance studies were conducted using the N-geneous® LDL-ST Cholesterol Reagents and two reference methods: N-geneous® LDL Cholesterol Reagent and ß-Quantification.
Seventy-seven serum samples, with LDL values between 54.5 and 222.1 mg/dL, were tested at Genzyme Corporation using the N-geneous® LDL-ST on the Olympus AU600 Analyzer and the Ngeneous® LDL methods. Of these 77 samples, 62 had sufficient volume to run ß-Quantification method.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies:
N-geneous® LDL-ST on the Olympus AU600 vs. ß-Quantification (n = 62): Slope: 1.08, Intercept (mg/dL): -8.7, Correlation Coefficient (r): 0.969, Mean (mg/dL) LDL-ST: 119.6, Mean (mg/dL) ß-Q: 119.0, Standard Deviation (mg/dL) LDL-ST: 28.9, Standard Deviation (mg/dL) ß-Q: 26.0, Mean Difference (mg/dL): 0.6, Mean Percent Difference (%): -0.1.
N-geneous® LDL-ST on the Olympus AU600 vs. N-geneous® LDL on Hitachi 911 (n = 77): Slope: 1.02, Intercept (mg/dL): -1.7, Correlation Coefficient (r): 0.990, Mean (mg/dL) LDL-ST: 121.6, Mean (mg/dL) LDL: 121.3, Standard Deviation (mg/dL) LDL-ST: 30.7, Standard Deviation (mg/dL) LDL: 29.9, Mean Difference (mg/dL): 0.3, Mean Percent Difference (%): 0.1.
Precision studies:
Within-Run Precision - Low (
§ 862.1475 Lipoprotein test system.
(a)
Identification. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
510(k) PREMARKET NOTIFICATION
| Genzyme Corporation |
|---|
| One Kendall Square |
| Cambridge, MA 02139 |
510(k) Summary Of Safety and Effectiveness Information Upon Which An Equivalence Determination Could be Made
| Trade or Proprietary Name: | Genzyme N-geneous® LDL-ST Cholesterol Reagent
Genzyme N-geneous® LDL-ST Cholesterol Calibrator
Genzyme LDL Control Set |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Common or Usual Name: | Homogeneous assay for low density lipoprotein cholesterol |
| Classification Name: | Low density lipoprotein cholesterol test
Calibrator, Primary
Low density lipoprotein control |
| Manufacturer: | Genzyme Diagnostics
One Kendall Square
Cambridge, MA 02139-1562 |
| Contact Person: | Robert Yocher, Vice President, Regulatory Affairs (617) 374-7275
Barbara Pizza, Manager, Regulatory Affairs (617) 252-7953. |
The use of the Genzyme N-geneous® LDL-ST Cholesterol Reagents in the clinical laboratory setting is substantially equivalent to the N-geneous® LDL Cholesterol Reagents and the B-Quantification methods.
The Genzyme N-geneous® LDL-ST Cholesterol Reagent is a two-reagent homogeneous method for the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum and plasma. This method is applicable to Olympus two-reagent Chemistry Analyzers and does not require any off-line pretreatment or centrifugation steps.
The principle of the test is based upon a unique detergent which selectively solubilizes only the non-LDL lipoproteins, allowing them to be removed by cholesterol enzymes prior to the LDL cholesterol reaction. The LDL particles remain intact. The hydrogen peroxide produced by the reaction of the enzymes with the released cholesterol is consumed by a peroxidase reaction with 4-aminoantipyrine, yielding a colorless product. A second detergent, capable of releasing LDL cholesterol molecules, is added. The enzyme reaction with LDL cholesterol in the presence of the coupler produces color which is proportional to the amount of LDL cholesterol in the sample.
Comparative performance studies were conducted using the N-geneous® LDL-ST Cholesterol Reagents and two reference methods: N-geneous® LDL Cholesterol Reagent and ß-Quantification.
1
510(k) PREMARKET NOTIFICATION
Seventy-seven serum samples, with LDL values between 54.5 and 222.1 mg/dL, were tested at Genzyme Corporation using the N-geneous® LDL-ST on the Olympus AU600 Analyzer and the Ngeneous® LDL methods. Of these 77 samples, 62 had sufficient volume to run ß-Quantification method.
| N-geneous® LDL-ST on the
Olympus AU600 | vs.
β-Quantification
(n = 62) | vs.
N-geneous® LDL on
Hitachi 911
(n = 77) |
|-------------------------------------------|-------------------------------------|-----------------------------------------------------|
| Slope | 1.08 | 1.02 |
| Intercept (mg/dL) | -8.7 | -1.7 |
| Correlation Coefficient (r) | 0.969 | 0.990 |
| Mean (mg/dL) | LDL-ST: 119.6
β-Q: 119.0 | LDL-ST: 121.6
LDL: 121.3 |
| Standard Deviation (mg/dL) | LDL-ST: 28.9
β-Q: 26.0 | LDL-ST: 30.7
LDL: 29.9 |
| Mean Difference (mg/dL) | 0.6 | 0.3 |
| Mean Percent Difference (%) | -0.1 | 0.1 |
ß-Q = ß-Quantification
Precision studies were conducted using the N-geneous® LDL-ST Cholesterol Reagents on the Olympus Analyzers. Both within-run and between-run studies were performed using Genzyme Desirable and Risk controls:
| Within-Run Precision | Low | High |
|---|---|---|
| ( Trade Name: N-geneous® LDL-ST Cholesterol Reagent Regulatory Class: I reserved P Product Code: MRR N-geneous® LDL-ST Cholesterol Calibrator Regulatory Class: II Product Code: JIS Genzyme LDL Cholesterol Control Set Regulatory Class: I reserved Product Code: JJX Dated: August 16, 1999 Received: August 17, 1999 |
Dear Ms. Pizza:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrlv/dsma/dsmamain.html".
Sincerely yours.
Steven Sutman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
3.0 INTENDED USE
Page 1 of __ 1
510(k) Number (if known): K993746
Device Name: _N-geneous® LDL-ST Cholesterol Reagent
N-geneous® LDL-ST Cholesterol Calibrator
Genzyme LDL Cholesterol Control Set
Indications for Use:
Reagents:
For the direct, quantitative determination of low-density lipoprotein cholesterol (LDL-C) in human serum or plasma.
Calibrator:
For the calibration of the N-geneous® LDL-ST Cholesterol assay in serum or plasma.
Controls:
To monitor the performance of the Genzyme Direct LDL Cholesterol, N-geneous® LDL Cholesterol and N-geneous® LDL-ST Cholesterol Reagents.
Tom Coker
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K992761
RxV
CTC
7